Description
Created On: 2020-07-15
Record Count: 3
Primary Industries
- Drugs
- Cancer
- cell therapy
- Disease
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 237216
Licensor shall offer to Licensee, on a priority basis with respect to any Third Party, all Products that Licensor plans to develop as Project Manager.
Licensor grants preferential terms to Licensee for two (2) rights for a Development Option, the Preferential Options, among the twenty (20) held by Licensee.
Licensor grants an irrevocable option, the Exclusive License Option, to obtain, based on the Final Development Results, an exclusive license, including vis-a-vis Licensor and its Affiliates, for its rights to the Industrial Property of the Product in order to sell the Final Product, to cause it to be sold, to exploit it, to cause it be exploited in the Territory in the therapeutic indication covered by the corresponding Marketing Authorization.
The Product shall be marketed by Licensee, its Affiliates or its licensees, under a trade name chosen by joint agreement between the Parties and registered in the name and on behalf of Licensor, hereinafter the Trade Name.
Licensor shall submit to Licensee as soon as possible following the execution date of this Memorandum of Agreement, all its on-going Development Programs outstanding.
Licensor shall transmit to Licensee, all information necessary to enable Licensee to evaluate its interest and possibly exercise a right for a Development Option to such On-going Programs.
Licensor shall provide Licensee, through the Research Committee, and as soon as possible after obtaining each of them, with the in vitro proof of concept for any Product under development at IDM, and the in vivo safety data for such Product in the first six (6) treated patients.
Licensee shall have an Exclusive License Option for each Development Program carried out to its term in application of this Memorandum of Agreement, or a maximum possible credit equal to twenty (20) Exclusive License Option rights.
Licensor shall supply the Product to Licensee in the form of the Final Product.
IPSCIO Record ID: 274811
Licensee may exercise its option and receive a worldwide exclusive license to certain intellectual property and an exclusive sublicense to certain intellectual property that Licensor has licensed from third parties, in each case, to develop, manufacture and commercialize HexaBody-CD38.
IPSCIO Record ID: 237235
For the Peptide License Option, Licensor grants a non-exclusive option, the Peptide Option, to include under the License any or all of the peptides listed hereto, the Specified Peptides, together with all associated patents and patent applications for BCL-A1 Candidates, BCL-A3 Supertype Candidates, BCL-A24 Candidates, and, BCL-B7 Supertype Candidates, as applicable, and any corresponding foreign counterparts thereof, and all patents issuing thereon, including utility, model and design patents and certificates of invention, including any division, continuation, continuation-in-part or substitution of any such patent application, and any reissue, extension, confirmation, registration, re-examination or inventors certificate of any such patent, together with any corresponding foreign counterparts of the foregoing, collectively, the Additional Rights.
For the Japan Option, Licensor grants an irrevocable option, the Japan Option, to include Japan in the Territory. The Japan Option may be exercised at any time during the term of this Agreement.
For the New Peptide Sequences, Licensor may upon its sole discretion offer for license to Licensee any new peptide sequence together with all associated patents and patent applications owned or licensed by Licensor.
